A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

ConclusionSLC3037, a NLRP3 inhibitor blocking NEK7 binding to NLRP3, could be a novel agent against diseases associated with NLRP3 inflammasome activation such as gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research